Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -930.25%, near the high end of its 5-year range (-8399.66%–69.26%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-930.25%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 643 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Fulcrum Therapeutics, Inc.
Market Cap
$283.44M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-930.25%
Market Cap
$286.16M
Net Profit Margin
-246.42%
TTM Avg
611.54%
3Y Avg
-783.13%
5Y Avg
-1134.34%
Market Cap
$278.62M
Net Profit Margin
-38.13%
TTM Avg
-18.76%
3Y Avg
-107.01%
5Y Avg
-249.44%
Market Cap
$290.35M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$275.74M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$275.66M
Net Profit Margin
-1941.09%
TTM Avg
-1708.77%
3Y Avg
-990.85%
5Y Avg
-815.81%
Market Cap
$292.42M
Net Profit Margin
-103.29%
TTM Avg
-83.69%
3Y Avg
-107.92%
5Y Avg
-85.90%
Market Cap
$293.99M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$267.45M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $283.44M | 0.00% | 0.00% | 0.00% | -930.25% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.16M | -246.42% | 611.54% | -783.13% | -1134.34% |
| Aurora Cannabis Inc. (ACB)vs › | $278.62M | -38.13% | -18.76% | -107.01% | -249.44% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $275.74M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fate Therapeutics, Inc. (FATE)vs › | $275.66M | -1941.09% | -1708.77% | -990.85% | -815.81% |
| Standard BioTools Inc. (LAB)vs › | $292.42M | -103.29% | -83.69% | -107.92% | -85.90% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $293.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.45M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $265.50M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 69.26% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -2842.25% |
| 2023-09-30 | -3164.30% |
| 2023-06-30 | -2702.61% |
| 2023-03-31 | -8399.66% |
| 2022-12-31 | -3815.33% |
| 2022-09-30 | -2006.59% |
| 2022-06-30 | -1810.31% |
| 2022-03-31 | -1000.31% |
| 2021-12-31 | -464.29% |
| 2021-09-30 | -419.78% |
| 2021-06-30 | -448.48% |
| 2021-03-31 | -354.96% |
| 2020-12-31 | -419.41% |
| 2020-09-30 | -1026.08% |
| 2020-06-30 | -784.25% |
| 2020-03-31 | -2460.27% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
